Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study
Main finding · MelanomaResult — go to the resultHazard ratio 0.77 95% CI 0.61–0.96Authors' conclusion
In this large, population-based cohort study, DPP-4 inhibitors were associated with a reduced risk of melanoma but not non-melanoma skin cancer, compared with sulfonylureas.
Study context
- Population
- Patients with T2D, UK Clinical Practice Research Datalink, 2007–2019two cohorts per outcome
- Exposure
- DPP-4i vs SU
- Outcome
- Incidence of melanoma and of non-melanoma skin cancer, separately
Methodological detailsnew-user active comparator, propensity score fine stratification weighted
- New-user active comparator
- Propensity score fine stratification weighted
Main finding
Melanoma
Hazard ratio
0.77
95% CI 0.61–0.96
By group
DPP-4i
49.7 per 100 000 person-years
SU
65.3 per 100 000 person-years
DPP-4ivs SU
HR 0.77 (95% CI 0.61–0.96)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Per 100 000 person-years
| Outcome | DPP-4i | SU | HR (95% CI) | |
|---|---|---|---|---|
| Non-melanoma skin cancer | 448.1 | 426.1 | 1.06 (0.98–1.15) | |
| Melanoma by cumulative duration of DPP-4i useDPP-4i 0-2 yearsvs SU | 1.14 (0.84–1.54) | |||
| Melanoma by cumulative duration of DPP-4i useDPP-4i 2.1-5 yearsvs SU | 0.44 (0.29–0.66) | |||
| Melanoma by cumulative duration of DPP-4i useDPP-4i >5 yearsvs SU | 0.33 (0.14–0.74) | |||
| 0.10.31310Hazard ratio (log scale) |
- Non-melanoma skin cancer: non-melanoma cohort: 96 411 DPP-4i and 208 626 SU users
Original publication
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. BMJ Open Diabetes Res Care. Published 10 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →